These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 28019722)

  • 1. Immunotherapeutic clearance of systemic amyloid deposits by antibodies to serum amyloid P component.
    Pepys MB
    Amyloid; 2017 Mar; 24(sup1):5-6. PubMed ID: 28019722
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
    Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
    Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
    Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immunohistochemical study of amyloid P component, apolipoprotein E and ubiquitin in human and murine amyloidoses.
    Cui D; Hoshii Y; Takahashi M; Kawano H; Iwata T; Ishihara T
    Pathol Int; 1998 May; 48(5):362-7. PubMed ID: 9704343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
    J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
    Gertz MA
    Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
    Lachmann HJ; Gallimore R; Gillmore JD; Carr-Smith HD; Bradwell AR; Pepys MB; Hawkins PN
    Br J Haematol; 2003 Jul; 122(1):78-84. PubMed ID: 12823348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid diseases: small drugs lead the attack.
    Iversen L
    Nature; 2002 May; 417(6886):231-3. PubMed ID: 12015581
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosis and management of systemic light chain AL amyloidosis.
    Bhutani D; Lentzsch S
    Pharmacol Ther; 2020 Oct; 214():107612. PubMed ID: 32562825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy.
    Pepys MB; Tennent GA; Booth DR; Bellotti V; Lovat LB; Tan SY; Persey MR; Hutchinson WL; Booth SE; Madhoo S; Soutar AK; Hawkins PN; Van Zyl-Smit R; Campistol JM; Fraser PE; Radford SE; Robinson CV; Sunde M; Serpell LC; Blake CC
    Ciba Found Symp; 1996; 199():73-81; discussion 81-9. PubMed ID: 8915605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis.
    Hazenberg BP; van Rijswijk MH; Piers DA; Lub-de Hooge MN; Vellenga E; Haagsma EB; Hawkins PN; Jager PL
    Am J Med; 2006 Apr; 119(4):355.e15-24. PubMed ID: 16564782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
    Baltz ML; Caspi D; Evans DJ; Rowe IF; Hind CR; Pepys MB
    Clin Exp Immunol; 1986 Dec; 66(3):691-700. PubMed ID: 3568456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supportive Care for Patients with Systemic Light Chain Amyloidosis.
    Wong SW; Fogaren T
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1177-1191. PubMed ID: 33099432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scintigraphic quantification and serial monitoring of human visceral amyloid deposits provide evidence for turnover and regression.
    Hawkins PN; Richardson S; MacSweeney JE; King AD; Vigushin DM; Lavender JP; Pepys MB
    Q J Med; 1993 Jun; 86(6):365-74. PubMed ID: 8171184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonamyloidotic monoclonal immunoglobulin deposits lack amyloid P component.
    Gallo G; Picken M; Frangione B; Buxbaum J
    Mod Pathol; 1988 Nov; 1(6):453-6. PubMed ID: 3146753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral Nervous System Involvement.
    Thaisetthawatkul P; Dyck PJB
    Hematol Oncol Clin North Am; 2020 Dec; 34(6):1091-1098. PubMed ID: 33099426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeting immunotherapy: a novel treatment approach for systemic amyloidosis.
    Wall JS; Foster JS; Martin EB; Kennel SJ
    Pharm Pat Anal; 2017 Sep; 6(5):215-223. PubMed ID: 28825509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic studies of radioiodinated serum amyloid P component in normal subjects and patients with systemic amyloidosis.
    Hawkins PN; Wootton R; Pepys MB
    J Clin Invest; 1990 Dec; 86(6):1862-9. PubMed ID: 2254450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.